Regulation & Policy
MHRA grants conditional approval to triheptanoin for rare inherited fatty acid disorders
The regulator has approved an oral liquid form of triheptanoin (Dojolvi) for adults and children with long-chain fatty acid oxidation disorders. The authorisation is conditional pending further paediatric data.

The Medicines and Healthcare products Regulatory Agency (MHRA) said on 30 October 2026 that it has approved an oral liquid form of triheptanoin, marketed as Dojolvi, for adults and children with long-chain fatty acid oxidation disorders (LC-FAOD).
The product has a conditional marketing authorisation. According to the MHRA, this is because further evidence of its efficacy and safety is needed from an ongoing paediatric study before a full marketing authorisation can be granted. The authorisation was granted on the same day to Ultragenyx Netherlands.
The condition and the treatment
The MHRA described LC-FAOD as a group of rare inherited disorders that affect adults and children of all ages. People with the conditions may have difficulty producing enough energy, the agency said, because the body cannot use long-chain fatty acids as an energy source. This puts them at risk of major clinical events that result in frequent hospitalisations.
Triheptanoin is a liquid taken daily by mouth as part of a carefully controlled diet. It is available only on prescription, and the MHRA said patients should take it exactly as directed by their healthcare professional. The agency said the medicine works by helping to prevent energy crises in cells that can cause muscle breakdown, damage to the heart muscle and low blood sugar.
The most common side effects, which the MHRA said may affect more than 1 in 10 people, are stomach pain, diarrhoea and vomiting. Anyone who suspects a side effect is encouraged to speak to a doctor, pharmacist or nurse and to report it through the Yellow Card scheme.
Julian Beach, MHRA Executive Director, Operations, said the agency was assured that the appropriate regulatory standards for approving the medicine had been met. He noted that people living with rare diseases often face significant barriers in accessing effective treatments. On safety monitoring, he said: “As with all products, we will keep the safety of triheptanoin under close review.”
The MHRA said the Summary of Product Characteristics and Patient Information leaflets will be published on its Products website within 7 days of approval.
Why it matters
The approval shows the MHRA granting a conditional authorisation for a rare-disease medicine while a paediatric study continues, which could be relevant to companies planning UK submissions with incomplete datasets. Ultragenyx Netherlands now holds the authorisation, and a full authorisation depends on further evidence. The announcement does not cover NHS funding, pricing or availability, so commercial teams would need to look elsewhere for those details.
Source: MHRA
Related stories

Regulation & Policy
MHRA publishes 2026–2030 plan to widen patient involvement in regulation

Regulation & Policy
MHRA extends Casgevy approval to children aged five and over with sickle cell disease and β-thalassaemia

Regulation & Policy
Government commits almost £140m to 14 urgent care schemes ahead of NHS winter